AVTR
BuyHot AirFLAGAvantor, Inc. · Healthcare · United States · $9.9B · Avg Vol: $113M/d
Hot Air: Rising on momentum alone: weak business, rich price.
Insufficient evidence for a screen-pass. Avantor, Inc.: fails the quant gate on quality (Q40/V50/M74; every leg must be >= 50). Absence of evidence is neutral; nothing adverse is known.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT AVANTOR, INC.
Read
Avantor, Inc. is a global provider of mission-critical products and services, supporting customers in the life sciences, advanced technologies, and applied materials sectors. The company benefits from its deeply embedded position in customer workflows, offering a vast portfolio of high-quality materials, equipment, and tailored services essential for research, development, and production. This indispensable role and extensive supply chain integration provide Avantor with a significant competitive moat.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.5B | 7.0B | 6.8B | 6.6B | -4.5% | 6.6B | 6.6B | 6.7B | 1.5% |
| EPS | 1.02 | 0.48 | 1.05 | -0.78 | 1.5% | -0.85 | — | — | — |
| Shares | 674.3M | 676.6M | 680.8M | 682.0M | +1.1% | 676.4M | — | — | — |
| Debt | 6.3B | 5.5B | 4.1B | 3.9B | -14.4% | 3.7B | — | — | — |
| Equity | 4.9B | 5.3B | 6.0B | 5.6B | 4.7% | — | — | — | — |
| Op CF | 843.6M | 870.0M | 840.8M | 623.8M | -9.6% | 597.0M | — | — | — |
| Inv CF | -109.6M | -143.7M | 438.9M | -130.5M | — | — | — | — | — |
| Fin CF | -648.7M | -843.7M | -1.3B | -409.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AVTR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AVTR | Avantor, Inc.(you) | $9.9B | 70 | Buy |
| ATR | AptarGroup, Inc. | $8.5B | 74 | Buy |
| BAX | Baxter International Inc. | $13.5B | 73 | Buy |
| COO | The Cooper Companies, Inc. | $13.9B | 64 | Hold |
| TFX | Teleflex Incorporated | $5.9B | 66 | Buy |
| ALGN | Align Technology, Inc. | $11.2B | 85 | Strong Buy |
| RGEN | Repligen Corporation | $9.9B | 50 | Hold |
| WST | West Pharmaceutical Services, Inc. | $23.7B | 74 | Buy |
| SOLV | Solventum Corporation | $15.5B | 83 | Strong Buy |
| ICUI | ICU Medical, Inc. | $4.4B | 63 | Hold |
Peer medians: ROE -31.0% · P/E 25.1x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.